Full Year 2026 Cipla Ltd Earnings Call Transcript
Key Points
- Cipla Ltd (BOM:500087) achieved significant milestones across its businesses, including surpassing 12,500 crores in revenues in India and scaling its EMU operations to a $400 million-plus business unit.
- The One India business delivered robust performance with a 15% year-on-year growth, driven by strong double-digit growth across branded prescription, generics, and consumer health.
- Cipla Ltd's North America business reported quarterly revenue of $155 million and an annual revenue of $780 million, supported by demand in its differentiated portfolio.
- The company has a strong pipeline with nearly 40 to 50 products to be filed over the next three years, including several respiratory and complex generic assets.
- Cipla Ltd is accelerating its AI-led transformation to drive efficiency, productivity, and better decision-making, supported by a robust data and technology foundation.
- The EBITDA margin for the quarter was 15.2%, which is lower than the annual margin of 21%, indicating potential margin pressures.
- Total expenses for the quarter increased by about 10% year-on-year, reflecting higher employee costs and ongoing geopolitical impacts.
- There are concerns about the impact of ongoing geopolitical situations on operating expenses, which could affect future quarters.
- The company has not factored in any contribution from its Landry site in FY27, indicating potential delays or issues with this facility.
- Cipla Ltd's guidance for EBITDA margins in the range of 18.5% to 20% for FY27 appears conservative given the expected growth in the U.S. and India businesses.
Ladies and gentlemen, good day and welcome to the Cipla Limited Q4 FY26 earnings conference call. (Operator Instructions) Please note that this conference is being recorded.
We have with us today Mr. Achin Gupta, MD and Global CEO; Mr. Ashish Adukia, Global CFO; and Ms. Diksha Maheshwari, Head, Investor Relations.
I would now like to hand the conference over to Ms. Diksha Maheshwari. Thank you, and over to you, ma'am.
Thank you, (inaudible) Good afternoon. Welcome to Q4 FY26 earnings call and from the Investor Relations team, et cetera.
Let me draw your attention to the fact that on this call our discussion will include certain forward-looking statements, which are predictions, projections, or other estimates about future events. These estimates reflect management's current expectations of the future performance of the company. Please note these estimates involve several risks and uncertainties that could cause our actual results to differ materially from what is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
